Ongoing projects
AXIS 1: CLINICAL AND TREATMENT RESEARCH
Healthy Brains, Healthy Lives: The McGill Brain Health Outcomes Platform (BHOP) - Mayo, BSc PT. PhD – McGill University
Real-time Auditory Feedback for Improving Gait and Walking in People with Parkinson’s Disease – Mayo, BSc PT. PhD – McGill University
Contribution of kinematic theory to early differential diagnosis of Parkinson’s disease – Blanchet, MD, PhD – Université de Montréal
Pre-clinical and clinical assessment of neurofibrillary tangles using novel tau ligand [18F]PI-2620 and assessment of synaptic density using another novel ligand [18F]SDM-8 : a pilot study – Rosa-Neto, MD PhD – McGill University
A Phase 1 Single- and Multiple-Ascending-Dose study to assess the safety, tolerability, and pharmacokinetics of BIIB094 administered intrathecally to adults with Parkinson’s disease – Postuma, MD – McGill University
Development of a novel, inexpensive and accessible battery of eye-tracking tests for diagnostic, disease progression, and response-to-treatment assessments of neurological disorders – Ducharme, MD – McGill University
Novel tools for the delivery and assessment of exercise programs adapted to individuals with Parkinson’s disease – Duval, PhD – Université du Québec à Montréal
The genetics of REM sleep behavior disorder, Parkinson’s disease and other synucleinopathies - Gan-Or, PhD – McGill University
Study of Electroretinogram (ERG) and Oral Bacteria in Parkinson’s disease: A Study of Markers in Parkinson’s disease – Lévesque, PhD – Université Laval
A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson’s Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation – Sanofi / Genzyme
Assessment of Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy - Postuma, MD, PhD – McGill University – Corporation abbVie
Behavioral and neuroimaging biomarkers of Parkinson’s Disease: Neuroimaging stream - Doyon, PhD – Université de Montréal and McGill University
Validation of a mobile app for the detection of tremors and bradykinesia – Duval, PhD – Université du Québec à Montréal
Exploratory study for the validation of magnetic resonance imaging biomarkers for Parkinson’s disease – Soucy, MD, PhD – Concordia University, Université de Montréal and CHUS
Effect of long-acting levodopa on obstructive sleep apnea in Parkinson’s disease – Kaminska, MD, MSc – McGill University
National Parkinson Foundation Patient Registry – Lafontaine, MD, MSC – McGill University / National Parkinson Foundation
Imaging brain structures involved in human walking with Parkinson’s disease (PD) – Paquette, PhD, Dr Soucy, MD – McGill University
A novel exercise modality to improve motor learning in PD - Roig, PhD – McGill University
AXIS 2: NON-MOTOR SYMPTOMS
Study of activity and functional connectivity in response to trigeminal odor in Parkinson’s disease - Frasnelli, PhD – Université du Québec à Trois-Rivières
Lighting-up the brain of patients with Parkinson’s disease – Carrier, PhD – Université de Montréal
Effects of Parkinson’s disease on social cognition and communication – Pell, PhD – McGill University
Longitudinal behavioral and neuroimaging study for the identification of language markers aimed at the earlier and more accurate prediction, detection, and tracking of cognitive decline over time in Parkinson’s disease – Auclair-Ouellet, PhD – McGill University
Understanding resilience and disease by using language and the brain to predict individual outcomes – Klein, PhD – McGill University
Identification of a specific olfactory disease profile in Parkinson’s disease – Frasnelli, PhD – Université du Québec à Trois-Rivières
Auditory dysfunction associated with Parkinson’s disease: a pilot study characterizing the peripheral and central auditory signs in Parkinson’s disease - Fuente, PhD – Uniersité de Montréal
Role of dopamine in prioritizing memory content: Implications for Parkinson’s disease – Sharp, MD, MSc – McGill University
Quantitative Motor Control for Decision-Making (QTMODEM) – Messier, PhD – Université de Montréal
MRI and Virtual Navigational Strategies in Parkinson’s Disease – Bohbot, PhD – McGill University and Université de Montréal
Role of brain cholinergic degenerations in the Mild Cognitive Impairment of Parkinson’s disease: A PET study with the 18F-Fluoroethoxybenzovesamicol (FEOBV) – Bédard, PhD, Soucy, MD, Dagher, MD – Université du Québec à Montréal, Université de Montréal and McGill University
AXIS 3: MOLECULAR AND CELLULAR BIOLOGY
Validation of salivary heme oxygenase-1 as a biomarker of idiopathic Parkinson’s disease – Schipper, MD, Ph. D – McGill University
Open Science Clinical Biological Imaging and Genetic Repository – C-BIG Repository
Targeted Next-Generation Sequencing and Genome-Wide Association Study of Parkinson’s disease patients in Quebec - Rouleau MD – McGill University
Epidemiological and genetic study of Parkinson’s disease in Quebec - Dupré, MD – CHU de Québec
Clinical – Genetic study of GBA mutations in Parkinson’s disease and REM sleep Behavior Disorder
———————————————————————————————–
Completed Project
AXIS 1: CLINICAL AND TREATMENT RESEARCH
Study on the effect of Mirtazapine on depression in patients diagnosed with Parkinson’s disease
Home and community mobility in elderly healthy individuals ans patients with Parkinson’s disease
The impact of drug-induced dyskinesia and its management on daily-life activities
Assessment of gait sensors for Parkinson’s disease
Comparison of the efficiency of levodopa and dopamine agonists on the mobility in the community and the physical activity level of people with Parkinson’s disease
Behavioral and neuroimaging biomarkers of Parkinson’s Disease: Behavioral stream – Doyon, PhD – UdeM and McGill
Impact of an exercise program on proprioceptive performance in Parkinson’s disease
Treatment of sleep apnea in Parkinson’s disease
Detection and automatic follow-up of the motor symptoms in patients with Parkinson’s disease
Caffeine as a Therapeutic Agent in Parkinson’s disease
Association of Cognitive dysfunction with Orthostatic Hypotension in patients with Parkinson’s disease
Validation of the Movement Disorders Society PD diagnostic criteria
The effect of cardiorespiratory exercice on motor skill learning in Parkinson’s disease
Freezing mechanisms in Parkinson’s disease
AXIS 2: NON-MOTOR SYMPTOMS
Smoking and Cognition in Parkinson’s disease
Cognitive effect of transcranial magnetic stimulation on patients with Parkinson’s disease and mild cognitive impairment
The Physical and Cognitive Benefits of Dance Movement Therapy for People with Parkinson’s Disease
Cognitive Reserve and Parkinson Disease : Can an extra Language help in more ways than one ?
Studying the resting-state networks associated with cognitive deficits in Parkinson’s disease
The effects of eye-movement training on cognitive performance
Perceptual-Cognitive Training in Parkinon’s disease
Electrical Brain Stitmulation and Impulsive Control Disorders
AXIS 3: MOLECULAR AND CELLULAR BIOLOGY
Genome wide association study of Parkinson’s disease and REM sleep Behavior Disorder
Targeted next generation sequencing of 58 Parkinson’s disease- related genes
The role of SMPD1 in Parkinson’s disease
Association study of the melanoma gene MC1R and Parkinson’s disease
The interplay between nicotinic receptor and nicotine metabolism genes, smoking and Parkinson’s disease
DNAJC13 in Parkinson’s disease
Study of novel familial genes in Parkinson’s disease
Replication study of essential tremor genetic loci in Parkinson’s disease
Study of HIP1R, LRRK2 and SNCA in Parkinson’s disease
